After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Spravato is made from esketamine ... your thoughts, feelings, or space and time); and breathing problems (including respiratory arrest). More on mental health: This story was originally featured ...

SPRAVATO® has proven to be a transformational treatment option for many patients with TRD by reducing depression symptoms in as little as 24 hours and reducing the time to relapse for patients wh ...

Johnson & Johnson's Spravato has been approved to treat a major ... based on individual needs," Mattingly added. "For the first time ever, we now have an option that gives patients freedom." ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

Spravato was first approved back in 2019, but at that time, patients had to use it with an oral antidepressant. Now, it’s been approved to use on its own. It’s for adults with major depressive ...

SPRAVATO® has proven to be a transformational treatment option for many patients with TRD by reducing depression symptoms in as little as 24 hours and reducing the time to relapse for ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.